CMC regulatory affairs specialists at pharmaceutical manufacturers use this agent when evaluating post-approval manufacturing changes to determine the correct regulatory reporting category — Prior Approval Supplement, Changes Being Effected, Annual Report — under FDA 21 CFR 314.70 and equivalent EMA variation categories. Miscategorisation leads to either enforcement risk or unnecessary approval delays.
Best with Claude
Clinical Trials & Regulatory Affairs
GMP Quality Systems & Manufacturing Regulatory Affairs